ALEPH-FARMS
3.11.2021 11:05:08 CET | Business Wire | Press release
Aleph Farms , the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced its detailed roadmap for achieving net zero carbon. In April 2020 , Aleph Farms first announced it would reach net zero within its operations by 2025, and throughout its entire supply chain by 2030. Today, Aleph Farms’ net zero carbon roadmap details its scope for achievement, strategic partnerships and the investments necessary to advance its environmental goals and business bottom line as the company delivers its quality cultivated beef steaks.
“The production of food is one of the largest sources of greenhouse gas emissions on the planet today, and a driving reason why Aleph Farms is making long-term sustainability a top priority,” said Dr. Lee Recht, VP sustainability at Aleph Farms. “Our roadmap represents significant research that will enable us to fulfill our commitment to total net zero within this decade and we strongly encourage other companies within the agrifood ecosystem to work to eliminate their carbon footprint as soon as possible.”
Aleph Farms’ roadmap to net zero carbon was created in partnership with Aimee Christensen, CEO of Christensen Global Strategies and a world-renowned expert in climate change and sustainability strategies. The roadmap to reduce the company’s carbon footprint includes optimized energy efficiency, transitioning renewable energy, offsetting and/or insetting unavoidable remaining emissions via reinvestment in decarbonizing Aleph Farms’ own production lines and supply chains.
“By building a company with a net zero mindset from nearly day one, Aleph Farms is pioneering the smart clean growth that all companies must take,” Christensen said. “By investing in energy efficiency and direct renewable energy supplies and similar strategies within its supply chain, Aleph Farms will benefit their bottom line now and even more in the future as carbon is priced around the world.”
As part of its roadmap, Aleph Farms has also signed a Memorandum of Understanding (MoU) with ENGIE Impact , the sustainability consulting arm of ENGIE . The two companies will work together to ensure Aleph Farms’ operations are net-zero compatible from the get-go, integrating energy efficiency, circularity in energy, as well as renewable energy and other strategic investments across Aleph’s production line and supply chains.
“We are delighted to work with Aleph Farms to support their net-zero strategy and vision to transform the meat industry,” said Nicolas Lefevre-Marton, Managing Director, EMEAI at ENGIE Impact. “We are deeply committed to helping bold organizations of all sizes around the world develop the right decarbonization goals, roadmaps and execution strategies to successfully achieve net-zero.”
In addition, Aleph Farms’ commitment to net zero carbon is being supported by a partnership with CE Delft , to analyze the life cycle impacts of Aleph Farms’ production line and supply chain, identifying hotspots and working to optimize the overall ecological footprint including carbon, water, waste and more. CE Delft recently conducted a study that found cultivated meat has the potential to reduce the carbon footprint of beef production by 92% when utilizing renewable sources of energy.
Aleph Farms is co-hosting an event alongside Food Tank at this year’s COP26 in Glasgow, Scotland on November 9, 2021. The panel, A New Approach to Meat , will discuss what it takes to change the production of animal protein and improve environmental impact while maintaining farmers' livelihoods and food security. The company’s white paper, An Inclusive Transition to a Sustainable and Resilient Meat Sector , highlights how transformational net zero carbon production systems can complement sustainable agricultural practices, supplying nutritional food to the growing population and strengthening global food security. To learn more about Aleph Farms' path to sustainability, please visit aleph-farms.com/sustainability .
About Aleph Farms
Aleph Farms grows beef steaks, from non-genetically engineered, non immortalized cells isolated from a living cow, without slaughtering the animal and with a significantly reduced impact to the environment. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub of the Strauss Group, and Professor Shulamit Levenberg from the Biomedical Engineering Faculty at the Technion - Israel Institute of Technology. The company’s vision is to provide unconditional nutrition for anyone, anytime, anywhere. For more information, follow Aleph Farms on Instagram , Twitter , Facebook or LinkedIn or visit www.aleph-farms.com . Access the Aleph Farms press kit here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005338/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
